ASND · Nasdaq · CIK 0001612042

Ascendis Pharma A/S

Ascendis Pharma A/S’s most recent SEC filing in our snapshot is a Form 6-K filed on Oct 26, 2026. In fiscal 2025 (year ended Dec 31, 2025) it reported revenue of EUR 720.1M and net income of -EUR 228.0M, according to its XBRL data on EDGAR. Its EDGAR record lists 9 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2025
EUR 720.1M
Net income, FY2025
-EUR 228.0M
Form 4 filings on record, past 12 months
9

Company overview

Legal name (as filed)
Ascendis Pharma A/S
Ticker
ASND
SEC Central Index Key (CIK)
0001612042
Industry (SIC)
Pharmaceutical Preparations (code 2834)
Business address
HELLERUP
State or country of incorporation
Denmark
Fiscal year ends
December 31
SEC filer category
Large accelerated filer
Position in SEC ticker list
#675 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from Ascendis Pharma A/S’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in EUR; the fiscal year is named for the calendar year in which it ends.

Revenue
EUR 7.8MFY2021EUR 51.2MFY2022EUR 266.7MFY2023EUR 363.6MFY2024EUR 720.1MFY2025
Net income
-EUR 383.6MFY2021-EUR 583.2MFY2022-EUR 481.4MFY2023-EUR 378.1MFY2024-EUR 228.0MFY2025
ASND annual results
ItemFY2021
ended Dec 31, 2021		FY2022
ended Dec 31, 2022		FY2023
ended Dec 31, 2023		FY2024
ended Dec 31, 2024		FY2025
ended Dec 31, 2025
RevenueEUR 7.8MEUR 51.2MEUR 266.7MEUR 363.6MEUR 720.1M
Net income-EUR 383.6M-EUR 583.2M-EUR 481.4M-EUR 378.1M-EUR 228.0M
Diluted EPS-EUR 7.00-EUR 10.40-EUR 8.55-EUR 6.53-EUR 3.76
Total assetsEUR 1.1BEUR 1.1BEUR 825.6MEUR 1.2BEUR 1.3B
Cash and equivalentsEUR 446.3MEUR 444.8MEUR 392.2MEUR 559.5MEUR 616.0M

XBRL tags used: revenue = Revenue; netIncome = ProfitLoss; assets = Assets; eps = DilutedEarningsLossPerShare; cash = CashAndCashEquivalents. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

ASND latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
Feb 11, 202620-FAnnual report of a foreign private issuer· period Dec 31, 2025Document · Index
Oct 26, 20266-KReport of a foreign private issuer· period Oct 26, 2026Document · Index

Recent SEC filings

The 40 newest documents filed by or about Ascendis Pharma A/S, by form type:

6-K ×214 ×9SCHEDULE 13G/A ×4144 ×33/A ×1SD ×1SCHEDULE 13G ×1
ASND recent filings
FiledFormWhat it isOriginal
Oct 26, 20266-KReport of a foreign private issuer· period Oct 26, 2026Document · Index
Oct 16, 20266-KReport of a foreign private issuer· period Oct 16, 2026Document · Index
Oct 14, 20266-KReport of a foreign private issuer· period Oct 14, 2026Document · Index
Sep 29, 20266-KReport of a foreign private issuer· period Sep 29, 2026Document · Index
Sep 28, 20264Statement of changes in beneficial ownership (insider trade)· period Apr 14, 2026Document · Index
Sep 15, 20266-KReport of a foreign private issuer· period Sep 14, 2026Document · Index
Sep 15, 20266-KReport of a foreign private issuer· period Sep 14, 2026Document · Index
Sep 9, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 8, 2026Document · Index
Sep 9, 20266-KReport of a foreign private issuer· period Sep 9, 2026Document · Index
Sep 9, 20266-KReport of a foreign private issuer· period Sep 9, 2026Document · Index
Sep 8, 2026144Notice of proposed sale of securitiesDocument · Index
Sep 3, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 2, 2026Document · Index
Sep 2, 2026144Notice of proposed sale of securitiesDocument · Index
Aug 31, 20266-KReport of a foreign private issuer· period Aug 31, 2026Document · Index
Aug 18, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 14, 2026Document · Index
Aug 13, 20266-KReport of a foreign private issuer· period Jun 30, 2026Document · Index
Aug 13, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Aug 13, 20266-KReport of a foreign private issuer· period Aug 13, 2026Document · Index
Aug 12, 20266-KReport of a foreign private issuer· period Aug 12, 2026Document · Index
Aug 6, 20266-KReport of a foreign private issuer· period Aug 6, 2026Document · Index
Jul 15, 20266-KReport of a foreign private issuer· period Jul 15, 2026Document · Index
Jun 30, 20266-KReport of a foreign private issuer· period Jun 30, 2026Document · Index
Jun 29, 20266-KReport of a foreign private issuer· period Jun 29, 2026Document · Index
Jun 17, 20266-KReport of a foreign private issuer· period Jun 17, 2026Document · Index
Jun 15, 20266-KReport of a foreign private issuer· period Jun 15, 2026Document · Index
Jun 12, 20266-KReport of a foreign private issuer· period Jun 12, 2026Document · Index
Jun 10, 20266-KReport of a foreign private issuer· period Jun 10, 2026Document · Index
Jun 2, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 2, 2026Document · Index
Jun 1, 20264Statement of changes in beneficial ownership (insider trade)· period May 29, 2026Document · Index
Jun 1, 20264Statement of changes in beneficial ownership (insider trade)· period May 29, 2026Document · Index
Jun 1, 20263/AInitial statement of beneficial ownership· period Mar 18, 2026Document · Index
May 27, 20264Statement of changes in beneficial ownership (insider trade)· period May 26, 2026Document · Index
May 22, 2026SDSpecialized disclosure report (conflict minerals)Document · Index
May 15, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
May 14, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
May 13, 20266-KReport of a foreign private issuer· period May 13, 2026Document · Index
May 12, 20264Statement of changes in beneficial ownership (insider trade)· period May 11, 2026Document · Index
May 11, 2026144Notice of proposed sale of securitiesDocument · Index
May 7, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
May 7, 2026SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index

Insider filing activity

9 Form 4 filings appear in Ascendis Pharma A/S’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Pharmaceutical Preparations

All 194 companies in Pharmaceutical Preparations

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Electronics Plaud Note Pro AI Voice Recorder An AI voice recorder that turns earnings calls and meetings into notes. View on Amazon → Electronics Amazon Kindle Paperwhite Signature Edition 32GB Read investing classics and long reports without eye strain. View on Amazon → Electronics Apple 2026 MacBook Air 13-inch Laptop A lightweight laptop for spreadsheets and filing research. View on Amazon →

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001612042 and XBRL company facts. Ascendis Pharma A/S on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.